Aqemia is a next-generation pharmatech company founded in 2019 as a deeptech spinoff from École Normale Supérieure that revolutionizes drug discovery by combining quantum-inspired physics algorithms with generative AI, enabling molecule exploration 10,000 times faster than conventional methods without requiring experimental training data, generating its own molecular data from first principles to guide AI-driven drug candidate discovery, with over $100 million in funding and major partnerships including a $140 million collaboration with Sanofi to accelerate oncology drug development through physics-based molecular design.
Maximilien Levesque (Co-founder, CEO), Emmanuel Briet (Co-founder, CTO)
Explore other quantum computing companies in similar categories or regions.
Private
$200M
2 funding rounds tracked. View detailed investment history →
Information for Educational Purposes Only: All information about Aqemia is provided for informational and educational purposes only. This is not investment, financial, or professional advice.
No Warranties: While we strive for accuracy, Quantum Zeitgeist makes no warranties regarding the accuracy, completeness, or timeliness of company information. The quantum technology industry evolves rapidly, and information may become outdated.
No Endorsement: Inclusion in Quantum Navigator does not constitute an endorsement, recommendation, or verification of Aqemia's claims, technology, or business viability.
Do Your Own Research: Always conduct independent due diligence and consult qualified professionals (financial advisors, lawyers, etc.) before making investment, business, or career decisions.
For more information, see our Terms of Service and Privacy Policy.